2,4-Dichloro-6-cyanoquinoline | 150453-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,4-Dichloro-6-cyanoquinoline
• 英文别名: 2,4-Dichloroquinoline-6-carbonitrile
• CAS: 150453-93-3
• 化学式: C₁₀H₄Cl₂N₂
• 分子量: 223.061
• InChiKey: WVFMAVUHEYKGLE-UHFFFAOYSA-N

物化性质

• 沸点：
  366.8±37.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,4-Dichloroquinoline-6-carboxamide 在 sodium chloride 、 碳酸氢钠 、 lithium chloride 、 三氯氧磷 作用下， 以 苯 为溶剂， 生成 2,4-Dichloro-6-cyanoquinoline
  参考文献：
  名称：

  Anti-ischemic 2,4-diaminoquinazolines

  摘要：

  这项发明涉及特定的2,4-二氨基喹唑啉化合物，它们的药用盐，包含这些化合物的药物组合物以及它们的治疗用途方法。这些化合物具有抗缺血活性。

  公开号：

  US05576322A1

文献信息

• NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1671962A1

  公开（公告）日：2006-06-21

  The compound represented by the general formula (I): wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R1 are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase(especially c-Jun N-terminalkinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

  化合物的一般式（I）：其中，融合环AB代表一个5-至10-成员的融合杂环；R1代表（1）氢原子，（2）卤素原子，（3）氰基，（4）氧基，（5）可选保护的羟基，（6）可选保护的羧基，（7）可选保护的氨基，（8）可能具有取代基的环状基团，（9）可能具有取代基的脂肪烃基团或（10）可选保护的硫醇基团; n代表0或1至8的整数; 假设n代表不小于2的整数，则复数R1相同或不同;其盐，溶剂化物或前药具有激酶（尤其是c-Jun N末端激酶）抑制活性和AP-1作为转录因子的功能抑制活性，因此可用作预防和/或治疗代谢疾病（例如糖尿病等）和炎症性风湿性关节炎等的药物。
• Novel fused heterocyclic compound and use thereof
  申请人：Yoshizawa Toshio

  公开号：US20070060595A1

  公开（公告）日：2007-03-15

  The compound represented by the general formula (I): wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R 1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent (s), (9) an aliphatic hydrocarbon group which may have a substituent (s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that n represents an integer of not less than 2, plural R 1 are the same or different; a salt thereof, a solvate thereof or a prodrug thereof has a kinase (especially c-Jun N-terminal kinase) inhibitory activity and an inhibitory activity of a function of AP-1 as a transcription factor, it is useful as a preventive and/or therapeutic agent for a for example, a diabetes of metabolic disease, etc., a rheumatoid arthritis of inflammatory, etc.

  化合物的一般式(I)表示的化合物：其中，融合环AB表示一个5-至10-成员的融合杂环；R1表示（1）氢原子，（2）卤原子，（3）氰基，（4）氧代基，（5）可选保护的羟基，（6）可选保护的羧基，（7）可选保护的氨基，（8）可能具有取代基（s）的环状基团，（9）可能具有取代基（s）的脂肪烃基团，或（10）可选保护的硫醇基团；n表示0或1至8的整数；但是，如果n表示不少于2的整数，则复数R1相同或不同；其盐、溶剂化物或前药具有激酶（特别是c-Jun N末端激酶）抑制活性和AP-1作为转录因子的功能抑制活性，因此它对于例如代谢性疾病的糖尿病等，炎症性的类风湿性关节炎等的预防和/或治疗剂是有用的。
• NITROGENOUS HETEROCYCLIC COMPOUND
  申请人：Eisai Co., Ltd.

  公开号：EP0607439A1

  公开（公告）日：1994-07-27

  A nitrogenous heterocyclic compound represented by general formula (I) or a pharmacologically acceptable salt thereof, efficacious in treating various ischemic cardiac diseases, wherein ring A represents a benzene, pyridine or cyclohexane ring; ring B represents a pyridine, pyrimidine or imidazole ring; R¹, R², R³ and R⁴ represent each hydrogen, halogen, lower alkoxy, etc.; R⁵ represents -NR¹¹R¹² (wherein R¹¹ and R¹² represent each hydrogen, lower alkyl, etc.), etc.; and R⁶ represents (a) (wherein R¹⁹ represents hydrogen, lower alkyl, etc.; R²⁰, R²¹ and R²² represent each hydrogen, halogen, hydroxy, etc.; and r represents an integer of 0.1 to 8), etc.

  一种由通式(I)代表的含氮杂环化合物或其药理学上可接受的盐，可有效治疗各种缺血性心脏病，其中环 A 代表苯环、吡啶环或环己烷环；环 B 代表吡啶环、嘧啶环或咪唑环；R¹、R²、R³ 和 R⁴ 分别代表氢、卤素、低级烷氧基等；R⁵ 代表 -NR¹R¹² (其中 R¹¹ 和 R¹² 分别代表氢、低级烷基等)；以及 R⁶ 代表 -NR¹R¹² (其中 R¹¹ 和 R¹² 分别代表氢、低级烷基等)。R⁵代表-NR¹R¹²（其中 R¹¹ 和 R¹² 分别代表氢、低级烷基等）等；以及 R⁶ 代表（a）（其中 R¹⁹ 代表氢、低级烷基等；R²⁰、R²¹ 和 R²² 分别代表氢、卤素、羟基等；以及 r 代表 0.1 至 8 的整数）等。
• COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF
  申请人：Hefei Industrial Pharmaceutical Institute Co., Ltd

  公开号：EP3708568A1

  公开（公告）日：2020-09-16

  The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.

  本公开涉及药物化学领域，尤其涉及一类抑制磷酸二酯酶4(I)的小分子化合物、其制备方法以及包含该化合物的药物组合物。药效学试验证明，本公开的化合物具有抑制 PDE-4 酶的活性和治疗炎症的疗效。
• Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof
  申请人：Hefei Industrial Pharmaceutical Institute Co., Ltd.

  公开号：US11161860B2

  公开（公告）日：2021-11-02

  The disclosure relates to the field of medicinal chemistry, in particular, to a class of small molecule compounds for inhibiting phosphodiesterase 4 (I), a preparation method thereof and a pharmaceutical composition comprising the compound. The pharmacodynamic test proves that the compound of the disclosure has the inhibitory activity of PDE-4 enzyme and the efficacy of inflammation treatment.

  本公开涉及药物化学领域，尤其涉及一类抑制磷酸二酯酶4(I)的小分子化合物、其制备方法以及包含该化合物的药物组合物。药效学试验证明，本公开的化合物具有抑制 PDE-4 酶的活性和治疗炎症的疗效。